Global /Israel /Healthcare /Biotechnology /RGNT

Regentis Biomaterials Ltd.

RGNT

• NYSEAMERICAN: RGNT • Delayed

2.93USD -2.3%

As of 5 June 2026, Regentis Biomaterials Ltd. has a market cap of $15.18M USD, ranking #38926 globally and #522 in Israel. It ranks #3474 in the Healthcare sector, and #680 in the Biotechnology industry.

Global Rank

38926

Country Rank

522

Sector Rank

3474

Industry Rank

680

Key Stats

Market Cap

$15.18MUSD

Enterprise Value

$9.36MUSD

Net Income (TTM)

-$13.69MUSD

PB Ratio

3.3

Company Profile

Country (HQ)

Israel

Sector

Healthcare

Industry

Biotechnology

CEO

Ehud Geller open_in_new

Employees

Founded

2004

IPO

04 Dec 2025

Website

regentis.co.il open_in_new

1d	1w	1m	3m	6m	YTD	1y	3y	5y
-2.3%	-4%	-9.5%	-56%	-77%	-58%	-77%	-77%	-77%

News

RGNT Analyst Forecasts

Markets

Exchange	Ticker	Price	Quotes
NYSE American (NYSEAMERICAN / AMEX) MIC: XASE PRIMARY	RGNT ISIN: IL0012190968 Shares Out.: Shares Outstanding: 5.179M¹ Shares Float: 2.485M² TV: TradingView: AMEX: RGNT SA: Stock Analysis: NYSEAMERICAN: RGNT YF: Yahoo Finance: RGNT GF: Google Finance: NYSEAMERICAN: RGNT NQ: NASDAQ: RGNT BA: Barron's: RGNT MS: Morningstar: XASE: RGNT	2.93 USD	TV: TradingView: AMEX: RGNT SA: Stock Analysis: NYSEAMERICAN: RGNT YF: Yahoo Finance: RGNT GF: Google Finance: NYSEAMERICAN: RGNT NQ: NASDAQ: RGNT BA: Barron's: RGNT MS: Morningstar: XASE: RGNT

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Regentis Biomaterials Ltd.

Regentis Biomaterials Ltd., a regenerative medicine company, develops and commercializes tissue repair solutions in the United States. It offers Gelrin, a platform based on hydrogel matrix of polyethylene glycol diacrylate and denatured fibrinogen for the treatment and regeneration of damaged or diseased tissue; and GelrinC, a cell-free and off-the-shelf hydrogel, which is in Phase II clinical trial for the treatment of cartilage injuries in the knee. The company was incorporated in 2004 and is based in Herzliya, Israel.

Similar Companies

Industry: Biotechnology (Israel)

Name	Market Cap (USD) diff.	PE	Country
Kamada Ltd. NASDAQ: KMDA	$470.55M 3K%	23.3	Israel
Israel Canada Hotels Ltd. TLV: DNA	$335.01M 962.09M ILS 2K%	267.3	Israel
Compugen Ltd. NASDAQ: CGEN	$245.84M 2K%	6.9	Israel
Enlivex Ltd. NASDAQ: ENLV	$190.26M 1K%	0.0	Israel
Kadimastem Ltd. TLV: KDST	$56.08M 161.06M ILS 270%	-	Israel
Pluri Inc. NASDAQ: PLUR	$34.07M 125%	-	Israel

Industry: Biotechnology (Global)

Name	Market Cap (USD) diff.	PE	Country
Amgen Inc. NASDAQ: AMGN	$182.42B 1M%	23.9	United States
Gilead Sciences, Inc. NASDAQ: GILD	$159.92B 1M%	19.0	United States
argenx SE EBR: ARGX	$48.01B 41.39B EUR 316K%	39.9	Netherlands
Samsung Biologics Co.,Ltd. KRX: 207940	$44.48B 68.19T KRW 293K%	35.5	South Korea
CSL Ltd. ASX: CSL	$43.01B 60.27B AUD 283K%	29.3	Australia
Lonza Group AG SIX: LONN	$42.55B 33.71B CHF 280K%	37.2	Switzerland

chevron_leftBack